New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

Hole,Stine; Pedersen,Astrid M.; Hansen,Susanne K.; Lundqvist,Johan; Yde,Christina W.; Lykkesfeldt,Anne E.

doi:10.3892/ijo.2015.2850

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

Authors:
- Stine Hole
- Astrid M. Pedersen
- Susanne K. Hansen
- Johan Lundqvist
- Christina W. Yde
- Anne E. Lykkesfeldt
View Affiliations

Affiliations: Breast Cancer Group, Cell Death and Metabolism, Danish Cancer Society Research Center, DK-2100 Copenhagen Ø, Denmark, Department of Biomedicine and Veterinary Public Health, Swedish University of Agricultural Sciences, Box 7028, SE-750 07 Uppsala, Sweden
Published online on: January 26, 2015 https://doi.org/10.3892/ijo.2015.2850
Pages: 1481-1490
Copyright: © Hole et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will be valuable tools to unravel the resistance mechanisms and to find new treatments and biomarkers. Cell culture models for acquired resistance to the three clinically relevant AIs letrozole, anastrozole and exemestane were developed by selection and expansion of colonies of MCF-7 breast cancer cells surviving long-term AI treatment under conditions where endogenous aromatase-mediated conversion of androgen to estrogen was required for growth. Four cell lines resistant to each of the AIs were established and characterized. Maintenance of ER expression and function was a general finding, but ER loss was seen in one of twelve cell lines. HER receptor expression was increased, in particular EGFR expression in letrozole-resistant cell lines. The AI-resistant cell lines had acquired ability to grow without aromatase-mediated conversion of testosterone to estradiol, but upon withdrawal of AI treatment, testosterone induced minor growth stimulation. Letrozole, exemestane and tamoxifen were able to abrogate the testosterone stimulation but could not reduce growth to below the level in standard growth medium with AI, demonstrating cross-resistance between letrozole, exemestane and tamoxifen. In contrast, fulvestrant totally blocked growth of the AI resistant cell lines both after withdrawal of AI and with AI treatment. These data show that ER is the main driver of growth of the AI-resistant cell lines and indicate ligand-independent activation of ER. Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs.

View Figures

View References

1	Early Breast Cancer Trialists’ Collaborative Group. Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
2	Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19:2596–2606. 2001.PubMed/NCBI
3	Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol. 18:3758–3767. 2000.
4	Paridaens RJ, Dirix LY, Beex LV, et al: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 26:4883–4890. 2008. View Article : Google Scholar : PubMed/NCBI
5	Dowsett M, Cuzick J, Ingle J, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 28:509–518. 2010. View Article : Google Scholar
6	Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
7	Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J and Johnston S: Lapatinib plus letrozole as first-line therapy for HER-2⁺ hormone receptor-positive metastatic breast cancer. Oncologist. 15:122–129. 2010. View Article : Google Scholar
8	Baselga J, Campone M, Piccart M, et al: Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar
9	Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
10	Miller WR: Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother. 11:1873–1887. 2010. View Article : Google Scholar : PubMed/NCBI
11	Arnedos M, Drury S, Afentakis M, et al: Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol. 25:605–610. 2014. View Article : Google Scholar : PubMed/NCBI
12	Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H and Shozu M: The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol. 86:219–224. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lykkesfeldt AE, Henriksen KL, Rasmussen BB, et al: In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. BMC Cancer. 9:1852009. View Article : Google Scholar : PubMed/NCBI
14	Haynes BP, Straume AH, Geisler J, et al: Intratumoral estrogen disposition in breast cancer. Clin Cancer Res. 16:1790–1801. 2010. View Article : Google Scholar : PubMed/NCBI
15	Lonning PE, Haynes BP, Straume AH, et al: Recent data on intratumor estrogens in breast cancer. Steroids. 76:786–791. 2011. View Article : Google Scholar : PubMed/NCBI
16	Briand P and Lykkesfeldt AE: Long-term cultivation of a human breast cancer cell line, MCF-7, in a chemically defined medium. Effect of estradiol. Anticancer Res. 6:85–90. 1986.PubMed/NCBI
17	Masamura S, Santner SJ, Heitjan DF and Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 80:2918–2925. 1995.PubMed/NCBI
18	Chan CM, Martin LA, Johnston SR, Ali S and Dowsett M: Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol. 81:333–341. 2002. View Article : Google Scholar : PubMed/NCBI
19	Coutts AS and Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res. 58:4071–4074. 1998.PubMed/NCBI
20	Pink JJ, Jiang SY, Fritsch M and Jordan VC: An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 55:2583–2590. 1995.PubMed/NCBI
21	Martin LA, Farmer I, Johnston SR, Ali S, Marshall C and Dowsett M: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 278:30458–30468. 2003. View Article : Google Scholar : PubMed/NCBI
22	Jensen J, Kitlen JW, Briand P, Labrie F and Lykkesfeldt AE: Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol. 84:469–478. 2003. View Article : Google Scholar : PubMed/NCBI
23	Santen RJ, Song RX, Zhang Z, et al: Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer. 12(Suppl 1): S61–S73. 2005. View Article : Google Scholar : PubMed/NCBI
24	Staka CM, Nicholson RI and Gee JM: Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer. 12(Suppl 1): S85–S97. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sabnis G and Brodie A: Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol. 340:142–147. 2011. View Article : Google Scholar
26	Martin LA, Ghazoui Z, Weigel MT, et al: An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids. 76:772–776. 2011. View Article : Google Scholar : PubMed/NCBI
27	Miller TW, Balko JM, Fox EM, et al: ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 1:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhou DJ, Pompon D and Chen SA: Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50:6949–6954. 1990.PubMed/NCBI
29	Sun XZ, Zhou D and Chen S: Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol. 63:29–36. 1997. View Article : Google Scholar
30	Macaulay VM, Nicholls JE, Gledhill J, Rowlands MG, Dowsett M and Ashworth A: Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells. Br J Cancer. 69:77–83. 1994. View Article : Google Scholar : PubMed/NCBI
31	Masri S, Phung S, Wang X, et al: Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res. 68:4910–4918. 2008. View Article : Google Scholar : PubMed/NCBI
32	Brodie A, Jelovac D, Sabnis G, Long B, Macedo L and Goloubeva O: Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol. 95:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
33	Masri S, Phung S, Wang X and Chen SA: Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol. 118:277–282. 2010. View Article : Google Scholar :
34	Wang X, Masri S, Phung S and Chen SU: The role of amphi-regulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res. 68:2259–2265. 2008. View Article : Google Scholar : PubMed/NCBI
35	Sonne-Hansen K and Lykkesfeldt AE: Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol. 93:25–34. 2005. View Article : Google Scholar : PubMed/NCBI
36	Lundqvist J, Hansen SK and Lykkesfeldt AE: Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim Biophys Acta. 1833.40–47. 2013.
37	Briand P and Lykkesfeldt AE: Effect of estrogen and anti-estrogen on the human breast cancer cell-line MCF-7 adapted to growth at low serum concentration. Cancer Res. 44:1114–1119. 1984.PubMed/NCBI
38	Lundholt BK, Briand P and Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 67:199–214. 2001. View Article : Google Scholar : PubMed/NCBI
39	Larsen MS, Yde CW, Christensen IJ and Lykkesfeldt AE: Carboplatin treatment of antiestrogen-resistant breast cancer cells. Int J Oncol. 41:1863–1870. 2012.PubMed/NCBI
40	Diaz-Cruz ES, Shapiro CL and Brueggemeier RW: Cyclo-oxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab. 90:2563–2570. 2005. View Article : Google Scholar
41	Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS and Yde CW: Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80. 2013. View Article : Google Scholar : PubMed/NCBI
42	Frogne T, Benjaminsen RV, Sonne-Hansen K, et al: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 114:263–275. 2009. View Article : Google Scholar :
43	Nicholson RI, Hutcheson IR, Jones HE, et al: Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord. 8:241–253. 2007. View Article : Google Scholar : PubMed/NCBI
44	Morrison G, Fu X, Shea M, et al: Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 144:263–272. 2014. View Article : Google Scholar : PubMed/NCBI
45	Weigel MT GZ, Dunbier A, Pancholi S, Dowsett M and Martin LA: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res. 14:R782012. View Article : Google Scholar : PubMed/NCBI
46	Brodie A, Macedo L and Sabnis G: Aromatase resistance mechanisms in model systems in vivo. J Steroid Biochem Mol Biol. 118:283–287. 2010. View Article : Google Scholar
47	Liu S, Meng X, Chen H, et al: Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 5:9049–9064. 2014.PubMed/NCBI
48	Jensen BL, Skouv J, Lundholt BK and Lykkesfeldt AE: Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182(R)-6. Br J Cancer. 79:386–392. 1999. View Article : Google Scholar : PubMed/NCBI
49	Dauvois S, Danielian PS, White R and Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 89:4037–4041. 1992. View Article : Google Scholar : PubMed/NCBI
50	Long BJ, Jelovac D, Thiantanawat A and Brodie AM: The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res. 8:2378–2388. 2002.PubMed/NCBI
51	Chia S, Gradishar W, Mauriac L, et al: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in post-menopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 26:1664–1670. 2008. View Article : Google Scholar : PubMed/NCBI
52	Johnston SR, Kilburn LS, Ellis P, et al: Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 14:989–998. 2013. View Article : Google Scholar : PubMed/NCBI
53	Miller WR and Larionov AA: Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res. 14:2012012. View Article : Google Scholar : PubMed/NCBI
54	Lonning PE: Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer. 45:527–535. 2009. View Article : Google Scholar
55	Pedersen AM, Thrane S, Lykkesfeldt AE and Yde CW: Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha. Int J Oncol. 45:2167–2175. 2014.PubMed/NCBI
56	Zheng XQ, Guo JP, Yang H, et al: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer. Oncogene. 33:4985–4996. 2014. View Article : Google Scholar
57	Thrane S, Pedersen AM, Thomsen MB, et al: A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. Nov 3–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
58	Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer. 83:1142–1152. 1998.
59	Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 16:453–461. 1998.PubMed/NCBI